Immunofluorescence and confocal microscopy Cells were labeled at 37 C with 1 M SNAP-Surface 488 in HEPES-bicarbonate buffer (120 mM NaCl, 4.8 mM KCl, 24 mM NaHCO 3 , 0.5 mM Na 2 HPO 4 , 5 mM HEPES, 2.5 mM CaCl 2 , and 1.2 mM MgCl 2 , saturated with 95% O 2 /5% CO 2 , pH 7.4) plus 3 mM glucose and 1% BSA, stimulated with agonists at 11 mM glucose for the indicated times, fixed and processed for immunofluorescence with mouse anti-Rab11 (610657, BD Biosciences, 1/20) or anti-rodent GLP-1R monoclonal antibody (Mab 7F38, DSHB, 2 g l 1 ) plus Alexa Fluor 546 secondary (Life Technologies, 1/200), mounted in Prolong Diamond antifade reagent with 4,6-diamidino-2-phenylindole (Life Technologies) and imaged with a Zeiss LSM-780 inverted confocal laser-scanning microscope in a 63/1.4 numerical aperture oil-immersion objective and analyzed in Image J

After achieving a healthy or desired weight, your Provider at Be Youthful Aesthetics will create a plan to create a plan to smoothly transition off the medication
If you are also dealing with nausea, diarrhea, constipation, or just eating much less than usual, electrolyte support may become even more important
For those considering switching rather than stopping entirely, comparing options like switching from tirzepatide to semaglutide or using conversion charts to move between medications helps maintain continuity of care during transitions
Liraglutide was approved by the EMA in 2009 and the US FDA in 2010 as a glucose-lowering therapy and at a higher dose by the US FDA for the treatment of obesity
GLP-1s for Osteoarthritis GLP-1 drugs may slow the progression of osteoarthritis, as research has found that people on the drugs lost more weight and had fewer knee surgeries than people not taking a GLP-1